Can I Take Melatonin with Addyi (Flibanserin)?

Why This Combination Comes Up

Flibanserin is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women, and it must be taken at bedtime because of its sedating properties [1]. Melatonin is the most widely used sleep supplement in the United States, with roughly 27.4 million adults reporting use in the 2023 NHIS supplement [2]. The overlap is predictable: a woman prescribed Addyi who already takes melatonin at night wants to know whether the two are safe together.

A Gap in the Literature

No randomized controlled trial has studied flibanserin and melatonin together. The FDA's prescribing information for Addyi does not mention melatonin by name [1]. That absence does not equal safety. It means the interaction assessment rests on pharmacologic reasoning, shared metabolic pathways, and overlapping side-effect profiles.

Who Should Pay Closest Attention

Women who experience dizziness or lightheadedness on flibanserin alone, those taking other CNS-depressant medications, and anyone with a history of orthostatic hypotension should discuss this combination with their prescriber before adding melatonin.

How Flibanserin Works in the Brain

Flibanserin is a multifunctional serotonin agonist and antagonist. It acts as a 5-HT1A receptor agonist and a 5-HT2A receptor antagonist, with weaker dopamine D4 receptor agonist activity [3]. The net effect is a shift in the balance between inhibitory serotonin signaling and excitatory dopamine/norepinephrine signaling in the prefrontal cortex.

Dosing and Sedation Profile

The approved dose is 100 mg taken once daily at bedtime. Sedation is the most common adverse effect, reported in 11.4% of patients in pooled phase III data compared to 5.1% on placebo [3]. Blood pressure drops of 6 to 10 mmHg systolic have been observed within 1 to 2 hours of dosing. These effects peak at roughly 1.5 hours post-dose and resolve within 6 hours in most patients.

Metabolism: The CYP3A4 Connection

Flibanserin is primarily metabolized by CYP3A4, with secondary contributions from CYP2C19 and minor involvement of CYP1A2 [1]. This metabolic profile is the reason flibanserin carries its boxed warning: moderate or strong CYP3A4 inhibitors (ketoconazole, fluconazole, certain macrolide antibiotics) can increase flibanserin exposure 4.5- to 7-fold, producing dangerous hypotension and syncope [1].

How Melatonin Is Metabolized

Melatonin undergoes extensive first-pass hepatic metabolism, primarily through CYP1A2, with minor contributions from CYP2C19 [4]. Its oral bioavailability is approximately 15%, and its plasma half-life is short at 20 to 50 minutes for immediate-release formulations.

Where the Metabolic Paths Cross

Both flibanserin and melatonin use CYP1A2 and CYP2C19 to some extent. The question is whether clinically meaningful competition occurs at those enzymes. Melatonin, even at 5 mg doses, produces plasma concentrations in the low nanomolar range and is unlikely to saturate CYP1A2 enough to meaningfully slow flibanserin clearance [4]. Flibanserin's CYP1A2 contribution is minor. The pharmacokinetic interaction risk is therefore low, though not zero.

CYP1A2 Inducers and Inhibitors Matter More

Cigarette smoking (a potent CYP1A2 inducer) and fluvoxamine (a strong CYP1A2 inhibitor) have far greater effects on melatonin levels than flibanserin does [5]. A woman taking fluvoxamine with both melatonin and flibanserin could see melatonin levels rise substantially, compounding sedation. This three-way interaction deserves prescriber attention.

The Real Risk: Pharmacodynamic Overlap

The more relevant concern is pharmacodynamic, not pharmacokinetic. Both drugs lower blood pressure and cause drowsiness through different mechanisms that stack on top of each other.

Additive CNS Depression

Flibanserin produces sedation via 5-HT1A agonism and 5-HT2A antagonism. Melatonin promotes sleep through MT1 and MT2 receptor activation in the suprachiasmatic nucleus and by reducing core body temperature [6]. These are distinct receptor pathways, which means co-administration can produce sedation that exceeds what either substance produces alone.

In the FDA's risk evaluation, concurrent use of flibanserin with other CNS depressants (benzodiazepines, opioids, diphenhydramine) was associated with increased rates of somnolence and dizziness [1]. Melatonin was not included in those studies, but the pharmacodynamic logic applies.

Blood Pressure Effects

Flibanserin reduces systolic blood pressure by an average of 6 mmHg within 2 hours of dosing [1]. Melatonin has a documented blood-pressure-lowering effect: a meta-analysis of 7 RCTs (N=221) found that controlled-release melatonin reduced nocturnal systolic BP by 6.1 mmHg (95% CI: -10.7 to -1.5) and diastolic BP by 3.5 mmHg [7]. Taking both at bedtime could produce a combined nocturnal systolic drop of 10 to 15 mmHg or more, increasing the risk of orthostatic hypotension if the patient gets up during the night.

Glucose Metabolism Considerations

Melatonin affects glucose tolerance. A study in 21 healthy women showed that a single 5 mg dose of melatonin taken 15 minutes before an oral glucose tolerance test impaired glucose tolerance by 54% (P<0.001) compared to placebo [8]. Flibanserin has no established effect on glucose metabolism. For women with prediabetes or insulin resistance, this melatonin-specific concern warrants monitoring, particularly if using higher melatonin doses.

Dose-Separation Strategies

Because flibanserin must be taken at bedtime and melatonin is typically taken 30 to 60 minutes before sleep, separating the two doses by several hours is impractical for most patients. A different approach is warranted.

Use the Lowest Effective Melatonin Dose

Physiologic melatonin doses (0.3 to 0.5 mg) produce blood levels comparable to the normal nocturnal peak and are effective for circadian entrainment [9]. Most commercial melatonin products contain 3 to 10 mg, which produces supraphysiologic levels. Starting at 0.5 mg reduces the pharmacodynamic overlap substantially.

Immediate-Release vs. Extended-Release

Immediate-release melatonin clears plasma within 60 to 90 minutes, concentrating its blood-pressure and sedation effects in a short window that overlaps heavily with flibanserin's peak. Extended-release melatonin produces lower peak concentrations spread over 6 to 8 hours [10]. For women on flibanserin, extended-release melatonin at 0.5 to 2 mg may produce a smoother pharmacodynamic profile with less risk of acute hypotension.

Timing Both at Bedtime

If both are taken at bedtime, sit on the bed before taking them. Do not stand up quickly during the first 2 hours. Keep water within arm's reach. These precautions mirror the FDA's general guidance for flibanserin use [1].

Monitoring Recommendations

No published guideline addresses monitoring for this specific combination. The following recommendations are derived from the FDA's Addyi REMS program and general pharmacovigilance principles.

First Two Weeks

During the first 14 days of combined use, check standing blood pressure each morning before getting out of bed. A systolic reading below 90 mmHg, or a drop of more than 20 mmHg from your seated baseline, should prompt a call to your prescriber.

Symptom Tracking

Track these symptoms daily for the first month:

• Dizziness on standing, especially during nighttime bathroom trips
• Morning grogginess lasting more than 30 minutes after waking
• Episodes of near-syncope or feeling faint
• Unusual daytime sleepiness

If any of these appear or worsen after adding melatonin, the melatonin dose should be reduced or discontinued before adjusting flibanserin.

Laboratory Monitoring

Routine labs are not required for this combination. Women with prediabetes or PCOS who use melatonin doses above 3 mg may benefit from periodic fasting glucose checks, given melatonin's effect on glucose tolerance [8].

What If You Are Already Taking Both

Many women discover this question after they have already been combining flibanserin and melatonin for weeks or months. If you have experienced no dizziness, orthostatic symptoms, or excessive sedation, the combination is likely being tolerated.

Do Not Abruptly Stop Flibanserin

Flibanserin does not cause physiologic dependence, but abrupt discontinuation can lead to return of HSDD symptoms within days [11]. If you decide to stop one of the two, discontinue melatonin first and assess whether your sleep quality changes before making further adjustments.

When to Escalate to Your Prescriber

Seek medical evaluation if you experience syncope (actual fainting), persistent dizziness that does not improve with lower melatonin doses, or if you are prescribed a new medication that inhibits CYP3A4 (such as fluconazole, clarithromycin, or certain HIV protease inhibitors). The addition of a CYP3A4 inhibitor to this combination raises flibanserin levels and magnifies all of the risks discussed above [1].

The Alcohol Variable

Flibanserin's boxed warning exists because of a severe interaction with alcohol: even moderate alcohol intake (2 standard drinks within 2 hours of the dose) increased the risk of clinically significant hypotension to 25% and syncope to 4% in a controlled study [1]. Melatonin adds a third sedating agent to that equation.

A Clear Rule

If you take flibanserin and melatonin together, do not drink alcohol within 2 hours of either dose. The FDA's recommendation to avoid alcohol entirely while on Addyi becomes more pressing when a second CNS-depressant supplement is in the mix [1].

Populations Needing Extra Caution

Women on Hormonal Contraceptives

Combined oral contraceptives containing ethinyl estradiol inhibit CYP1A2, which can increase melatonin levels by 50% to 200% [12]. Women taking flibanserin, melatonin, and a combined oral contraceptive face higher melatonin exposure and potentially greater sedation and blood pressure effects.

Women Over 40 Approaching Perimenopause

Flibanserin is approved only for premenopausal women. Those in late reproductive years may have declining estrogen levels that alter CYP enzyme activity [13]. Perimenopause also increases the prevalence of sleep disturbance, making melatonin use more common in exactly the population most likely to be prescribed Addyi.

Women Taking SSRIs or SNRIs

HSDD is more common among women on antidepressants, yet SSRIs and SNRIs have serotonergic activity that can interact with flibanserin's 5-HT1A agonism. Adding melatonin to this combination creates a three-layer sedation risk. Prescribers should review the full medication list before approving the addition of melatonin.

What the Evidence Does Not Tell Us

No study has measured flibanserin's AUC or Cmax with and without concurrent melatonin. No trial has tracked sexual desire outcomes in women taking both agents. The safety assessment presented here is built on pharmacologic extrapolation, not on direct clinical data. This is a gap that future research should address.

The most conservative reading of the available evidence: the combination is likely tolerable at low melatonin doses (0.3 to 1 mg) in women who are not taking CYP3A4 inhibitors, are not drinking alcohol, and are not experiencing orthostatic symptoms on flibanserin alone. Women outside those parameters should consult their prescriber before combining.